Immuno-Oncology 2016: Sponsor Profiles

Platinum sponsor

Bristol-Myers Squibb

Bristol-Myers-Squibb logo

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
www.bms.com

Booth number: 6

Silver sponsor

AstraZeneca

AstraZeneca Logo with Payoff

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease. At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.
www.astrazeneca.com

Booth number: 4

F. Hoffmann - La Roche Ltd

Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
www.roche.com

Bronze sponsor

Lilly Oncology

Lilly Oncology Logo

For more than 50 years, Lilly Oncology has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit the company website.
www.LillyOncology.com

Merck-Pfizer Alliance

Merck KGaA Pfizer Logo Blue Violet

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody.

Booth number: 5

Pfizer

Pfizer Logo 2015

Pfizer Oncology is committed to the research and discovery of breakthrough treatment options, including small molecules, biologics and immunotherapies, to improve the outlook for cancer patients worldwide. For more information please visit the company website.
www.pfizer.com

Booth number: 7

Supporter

Fluidigm Corporation

fluidigm-corporation-logo

Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate immune cell function and the tumor microenvironment with unprecedented resolution. Using proven mass cytometry and microfluidic technologies, we provide workflows to identify and characterize changes in cellular phenotypes at single-cell resolution. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough. Together we will transform the future of cancer care.
www.fluidigm.com

Booth number: 3

NanoString Technologies

Nanostring Logo

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is marketed for use on the nCounter Dx Analysis System which is FDA 510(k) cleared.
www.nanostring.com

Booth number: 10